Advertisement

European Radiology

, Volume 25, Issue 8, pp 2460–2469 | Cite as

18 F-FDG PET/CT for initial staging in breast cancer patients – Is there a relevant impact on treatment planning compared to conventional staging modalities?

  • J. Krammer
  • A. Schnitzer
  • C. G. Kaiser
  • K. A. Buesing
  • E. Sperk
  • J. Brade
  • S. Wasgindt
  • M. Suetterlin
  • S. O. Schoenberg
  • E. J. Sutton
  • K. Wasser
Breast

Abstract

Objective

To evaluate the impact of whole-body 18 F-FDG PET/CT on initial staging of breast cancer in comparison to conventional staging modalities.

Methods

This study included 102 breast cancer patients, 101 patients were eligible for evaluation. Preoperative whole-body staging with PET/CT was performed in patients with clinical stage ≥ T2 tumours or positive local lymph nodes (n = 91). Postoperative PET/CT was performed in patients without these criteria but positive sentinel lymph node biopsy (n = 10). All patients underwent PET/CT and a conventional staging algorithm, which included bone scan, chest X-ray and abdominal ultrasound. PET/CT findings were compared to conventional staging and the impact on therapeutic management was evaluated.

Results

PET/CT led to an upgrade of the N or M stage in overall 19 patients (19 %) and newly identified manifestation of breast cancer in two patients (2 %). PET/CT findings caused a change in treatment of 11 patients (11 %). This is within the range of recent studies, all applying conventional inclusion criteria based on the initial T and N status.

Conclusions

PET/CT has a relevant impact on initial staging and treatment of breast cancer when compared to conventional modalities. Further studies should assess inclusion criteria beyond the conventional T and N status, e.g. tumour grading and receptor status.

Key Points

PET/CT may be relevant in staging breast cancer patients at higher risk for metastases

PET/CT may modify the N and M stage in multiple patients

PET/CT may impact treatment planning in breast cancer patients

Keywords

PET/CT Breast Cancer Staging Treatment Conventional Imaging 

Notes

Acknowledgments

We would like to thank Wolfgang A. Weber, Molecular Imaging and Therapy Service at the Memorial Sloan-Kettering Cancer Centre New York for critically reading and reviewing the manuscript. The scientific guarantor of this publication is Professor Dr. med. Stefan O. Schoenberg, Institute of Clinical Radiology and Nuclear Medicine, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg. The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article. The authors state that this work has not received any funding. Joachim Brade kindly provided statistical advice for this manuscript. Institutional Review Board approval was obtained. Written informed consent was obtained from all subjects (patients) in this study. Methodology: prospective, diagnostic or prognostic study, performed at one institution

References

  1. 1.
    R. Kreienberg: Interdisciplinary S3 Guidelines for the Diagnosis, Treatment and Follow-up Care Breast Cancer, 3rd updated version., 3 edn. München: Zuckerschwerdt Verlag; 2012Google Scholar
  2. 2.
    Senkus E, Kyriakides S, Penault-Llorca F, Poortmans P, Thompson A, Zackrisson S, Cardoso F, Group EGW (2013) Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 24:vi7–vi23PubMedCrossRefGoogle Scholar
  3. 3.
    Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, Stine SH, Coleman RE (2008) Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 26:2155–2161PubMedCrossRefGoogle Scholar
  4. 4.
    Groheux D, Giacchetti S, Espie M, Vercellino L, Hamy AS, Delord M, Berenger N, Toubert ME, Misset JL, Hindie E (2011) The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study. J Nucl Med 52:1526–1534PubMedCrossRefGoogle Scholar
  5. 5.
    Fuster D, Duch J, Paredes P, Velasco M, Munoz M, Santamaria G, Fontanillas M, Pons F (2008) Preoperative staging of large primary breast cancer with [18F]fluorodeoxyglucose positron emission tomography/computed tomography compared with conventional imaging procedures. J Clin Oncol 26:4746–4751PubMedCrossRefGoogle Scholar
  6. 6.
    Heusner TA, Kuemmel S, Umutlu L, Koeninger A, Freudenberg LS, Hauth EA, Kimmig KR, Forsting M, Bockisch A, Antoch G (2008) Breast cancer staging in a single session: whole-body PET/CT mammography. J Nucl Med 49:1215–1222PubMedCrossRefGoogle Scholar
  7. 7.
    Aukema TS, Rutgers EJ, Vogel WV, Teertstra HJ, Oldenburg HS, Vrancken Peeters MT, Wesseling J, Russell NS, Valdes Olmos RA (2010) The role of FDG PET/CT in patients with locoregional breast cancer recurrence: a comparison to conventional imaging techniques. Eur J Surg Oncol 36:387–392PubMedCrossRefGoogle Scholar
  8. 8.
    Alberini JL, Lerebours F, Wartski M, Fourme E, Le Stanc E, Gontier E, Madar O, Cherel P, Pecking AP (2009) 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer. Cancer 115:5038–5047PubMedCrossRefGoogle Scholar
  9. 9.
    Groheux D, Espie M, Giacchetti S, Hindie E (2013) Performance of FDG PET/CT in the clinical management of breast cancer. Radiology 266:388–405PubMedCrossRefGoogle Scholar
  10. 10.
    Busing KA, Schonberg SO, Brade J, Wasser K (2013) Impact of blood glucose, diabetes, insulin, and obesity on standardized uptake values in tumours and healthy organs on 18F-FDG PET/CT. Nucl Med Biol 40:206–213PubMedCrossRefGoogle Scholar
  11. 11.
    Zincirkeser S, Sahin E, Halac M, Sager S (2007) Standardized uptake values of normal organs on 18F-fluorodeoxyglucose positron emission tomography and computed tomography imaging. J Int Med Res 35:231–236PubMedCrossRefGoogle Scholar
  12. 12.
    Wasser K, Schnitzer A, Brade J (2010) Schoenberg SO: [Non-invasive imaging modalities for preoperative axillary lymph node staging in patients with breast cancer]. Radiologe 50:1022–1029PubMedCrossRefGoogle Scholar
  13. 13.
    Ueda S, Tsuda H, Asakawa H, Omata J, Fukatsu K, Kondo N, Kondo T, Hama Y, Tamura K, Ishida J et al (2008) Utility of 18F-fluoro-deoxyglucose emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in combination with ultrasonography for axillary staging in primary breast cancer. BMC Cancer 8:165PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Chung A, Liou D, Karlan S, Waxman A, Fujimoto K, Hagiike M, Phillips EH (2006) Preoperative FDG-PET for axillary metastases in patients with breast cancer. Arch Surg 141:783–788, discussion 788–789PubMedCrossRefGoogle Scholar
  15. 15.
    Edge SB, Compton CC (2010) The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 17:1471–1474PubMedCrossRefGoogle Scholar
  16. 16.
    Brito RA, Valero V, Buzdar AU, Booser DJ, Ames F, Strom E, Ross M, Theriault RL, Frye D, Kau SW et al (2001) Long-term results of combined-modality therapy for locally advanced breast cancer with ipsilateral supraclavicular metastases: The University of Texas M.D. Anderson Cancer Centre experience. J Clin Oncol 19:628–633PubMedGoogle Scholar
  17. 17.
    Early and locally advanced breast cancer: diagnosis and treatment National Institute for Health and Clinical Excellence guideline 2009Google Scholar
  18. 18.
    Veronesi U, De Cicco C, Galimberti VE, Fernandez JR, Rotmensz N, Viale G, Spano G, Luini A, Intra M, Veronesi P et al (2007) A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol 18:473–478PubMedCrossRefGoogle Scholar
  19. 19.
    Pace L, Nicolai E, Luongo A, Aiello M, Catalano OA, Soricelli A, Salvatore M (2014) Comparison of whole-body PET/CT and PET/MRI in breast cancer patients: lesion detection and quantitation of 18F-deoxyglucose uptake in lesions and in normal organ tissues. Eur J Radiol 83:289–296PubMedCrossRefGoogle Scholar
  20. 20.
    Cochet A, Dygai-Cochet I, Riedinger JM, Humbert O, Berriolo-Riedinger A, Toubeau M, Guiu S, Coutant C, Coudert B, Fumoleau P et al (2014) (18)F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations. Eur J Nucl Med Mol Imaging 41:428–437PubMedCrossRefGoogle Scholar
  21. 21.
    Sen F, Akpinar AT, Ogur U, Duman G, Tamgac F, Alper E (2013) The impact of PET/CT imaging performed in the early postoperative period on the management of breast cancer patients. Nucl Med Commun 34:571–576PubMedCrossRefGoogle Scholar
  22. 22.
    Garami Z, Hascsi Z, Varga J, Dinya T, Tanyi M, Garai I, Damjanovich L, Galuska L (2012) The value of 18-FDG PET/CT in early-stage breast cancer compared to traditional diagnostic modalities with an emphasis on changes in disease stage designation and treatment plan. Eur J Surg Oncol 38:31–37PubMedCrossRefGoogle Scholar
  23. 23.
    Riegger C, Herrmann J, Nagarajah J, Hecktor J, Kuemmel S, Otterbach F, Hahn S, Bockisch A, Lauenstein T, Antoch G et al (2012) Whole-body FDG PET/CT is more accurate than conventional imaging for staging primary breast cancer patients. Eur J Nucl Med Mol Imaging 39:852–863PubMedCrossRefGoogle Scholar
  24. 24.
    Bernsdorf M, Berthelsen AK, Wielenga VT, Kroman N, Teilum D, Binderup T, Tange UB, Andersson M, Kjaer A, Loft A et al (2012) Preoperative PET/CT in early-stage breast cancer. Ann Oncol 23:2277–2282PubMedCrossRefGoogle Scholar
  25. 25.
    Groheux D, Moretti JL, Baillet G, Espie M, Giacchetti S, Hindie E, Hennequin C, Vilcoq JR, Cuvier C, Toubert ME et al (2008) Effect of (18)F-FDG PET/CT imaging in patients with clinical Stage II and III breast cancer. Int J Radiat Oncol Biol Phys 71:695–704PubMedCrossRefGoogle Scholar
  26. 26.
    Koolen BB, Vrancken Peeters MJ, Aukema TS, Vogel WV, Oldenburg HS, van der Hage JA, Hoefnagel CA, Stokkel MP, Loo CE, Rodenhuis S et al (2012) 18F-FDG PET/CT as a staging procedure in primary stage II and III breast cancer: comparison with conventional imaging techniques. Breast Cancer Res Treat 131:117–126PubMedCrossRefGoogle Scholar
  27. 27.
    de Azambuja E, Cardoso F, De Jr. Castro G, Colozza M, Mano MS, Durbecq V, Sotiriou C, Larsimont D, Piccart-Gebhart MJ, Paesmans M (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96:1504–1513PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res Off J Am Assoc Cancer Res 13:4429–4434CrossRefGoogle Scholar

Copyright information

© European Society of Radiology 2015

Authors and Affiliations

  • J. Krammer
    • 1
  • A. Schnitzer
    • 1
  • C. G. Kaiser
    • 1
  • K. A. Buesing
    • 1
  • E. Sperk
    • 2
  • J. Brade
    • 3
  • S. Wasgindt
    • 4
  • M. Suetterlin
    • 4
  • S. O. Schoenberg
    • 1
  • E. J. Sutton
    • 5
  • K. Wasser
    • 1
  1. 1.Institute of Clinical Radiology and Nuclear Medicine, University Medical Centre Mannheim, Medical Faculty MannheimUniversity of HeidelbergMannheimGermany
  2. 2.Department of Radiation Oncology, University Medical Centre Mannheim, Medical Faculty MannheimUniversity of HeidelbergMannheimGermany
  3. 3.Institute of Medical Statistics, Biomathematics and Data Processing, Medical Faculty MannheimUniversity of HeidelbergMannheimGermany
  4. 4.Department of Gynaecology and Obstetrics, University Medical Centre Mannheim, Medical Faculty MannheimUniversity of HeidelbergMannheimGermany
  5. 5.Department of RadiologyMemorial Sloan-Kettering Cancer Center, Evelyn H. Lauder Breast CenterNew YorkUSA

Personalised recommendations